OPTN vs. CNTX, AMLX, KPTI, PDSB, NVCT, RNAC, VTGN, DMAC, COYA, and MCRB
Should you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include Context Therapeutics (CNTX), Amylyx Pharmaceuticals (AMLX), Karyopharm Therapeutics (KPTI), PDS Biotechnology (PDSB), Nuvectis Pharma (NVCT), Cartesian Therapeutics (RNAC), Vistagen Therapeutics (VTGN), DiaMedica Therapeutics (DMAC), Coya Therapeutics (COYA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
Context Therapeutics (NASDAQ:CNTX) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.
Context Therapeutics has higher earnings, but lower revenue than OptiNose. OptiNose is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, OptiNose had 9 more articles in the media than Context Therapeutics. MarketBeat recorded 20 mentions for OptiNose and 11 mentions for Context Therapeutics. OptiNose's average media sentiment score of 0.84 beat Context Therapeutics' score of 0.09 indicating that Context Therapeutics is being referred to more favorably in the media.
14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 85.6% of OptiNose shares are held by institutional investors. 9.4% of Context Therapeutics shares are held by company insiders. Comparatively, 2.2% of OptiNose shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Context Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 233.33%. OptiNose has a consensus target price of $3.67, indicating a potential upside of 184.24%. Given OptiNose's higher probable upside, equities analysts plainly believe Context Therapeutics is more favorable than OptiNose.
OptiNose received 231 more outperform votes than Context Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Context Therapeutics an outperform vote while only 63.31% of users gave OptiNose an outperform vote.
Context Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500.
Context Therapeutics has a net margin of 0.00% compared to Context Therapeutics' net margin of -50.06%. Context Therapeutics' return on equity of 0.00% beat OptiNose's return on equity.
Summary
Context Therapeutics beats OptiNose on 9 of the 16 factors compared between the two stocks.
Get OptiNose News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptiNose Competitors List
Related Companies and Tools
